603456 九洲药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,160,4884.92%5,160,5855,523,4185,445,1054,063,182
减:营业总成本3,195,3350.14%4,227,8114,275,8354,281,4543,332,436
    其中:营业成本2,598,1610.42%3,417,1693,443,4933,557,8162,709,051
               财务费用(17,826)-64.14%(77,849)(75,635)(86,168)37,195
               资产减值损失(90,619)134.58%(218,482)(78,204)(59,326)(50,811)
公允价值变动收益--------(35,222)(1,390)
投资收益(2,938)-36.54%(8,132)(19,364)2,07061,068
    其中:对联营企业和合营企业的投资收益(4,278)-48.38%(11,955)(7,756)591,199
营业利润912,35122.12%732,1861,175,7711,107,912753,635
利润总额909,80721.84%730,6021,180,6421,103,822744,740
减:所得税费用161,13341.52%123,535149,270182,848110,589
净利润748,67418.30%607,0681,031,372920,973634,151
减:非控股权益1,022-48.30%971(1,884)(197)250
股东净利润747,65318.51%606,0961,033,256921,170633,901

市场价值指针
每股收益 (元) *0.84020.00%0.6801.1601.1100.770
每股派息 (元) *0.200--0.3000.5000.4000.250
每股净资产 (元) *9.8433.56%9.5369.4076.3495.497
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容